Lifecore kept at strong buy from JMP

JMP Securities analyst Anthony Ostrea maintained Lifecore Biomedical, Inc. at a strong buy rating, with an increased price target of $20, from $18. The company reported in line first-quarter 2007 results with revenue up 12% year-over-year at $15.0 million and GAAP earnings per share of $0.08. While the company reported lower Hyaluronan sales, the primary growth driver (dental implants) remains healthy, according to the analyst. Shares of the Chaska, Minn.-based biotechnology company were down 56 cents, or 3.66%, at $14.73. (Nasdaq: LCBM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.